Table 2.
Clinicopathological features according to radiosensitivity after PSM
| RR(Cluster1) | RS(Cluster2) | Total | P-value | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| N | % | N | % | N | % | |||||
| Age | <60 | 89 | 45.9 | 80 | 41.2 | 169 | 43.6 | 0.431a | ||
| ≥60 | 105 | 54.1 | 114 | 58.8 | 219 | 56.4 | ||||
| Gender | Female | 47 | 24.2 | 60 | 30.9 | 107 | 27.6 | 0.154 | ||
| Male | 147 | 75.8 | 134 | 69.1 | 281 | 72.4 | ||||
| Alcohol | No | 59 | 30.4 | 62 | 32 | 121 | 31.2 | 0.570 | ||
| Yes | 129 | 66.5 | 130 | 67 | 259 | 66.8 | ||||
| unknown | 6 | 3.1 | 2 | 1 | 8 | 2.1 | ||||
| Packs/year | <40 | 131 | 67.5 | 130 | 67 | 261 | 67.3 | 1.000 | ||
| ≥40 | 63 | 32.5 | 64 | 33 | 127 | 32.7 | ||||
| HPV | Negative | 24 | 12.4 | 28 | 14.4 | 52 | 13.4 | 0.075 | ||
| Positive | 3 | 1.5 | 12 | 6.2 | 15 | 3.9 | ||||
| unknown | 167 | 86.1 | 154 | 79.4 | 321 | 82.7 | ||||
| P16 | Negative | 27 | 13.9 | 31 | 16 | 58 | 14.9 | 0.018 | ||
| Positive | 6 | 3.1 | 19 | 9.8 | 25 | 6.4 | ||||
| unknown | 161 | 83 | 144 | 74.2 | 305 | 78.6 | ||||
| EGFR status | Unamplified | 4 | 1.3 | 11 | 5.7 | 15 | 3.9 | 0.067 | ||
| Amplified | 7 | 3.6 | 1 | 0.5 | 8 | 2.1 | ||||
| unknown | 183 | 94.3 | 182 | 93.8 | 365 | 94.1 | ||||
| Anatomic | Hypopharynx | 3 | 1.5 | 4 | 2.1 | 7 | 1.8 | 0.670 | ||
| Larynx | 39 | 20.1 | 49 | 25.3 | 88 | 22.7 | ||||
| Oral | 152 | 78.4 | 141 | 72.7 | 293 | 75.5 | ||||
| Grade | G1 | 19 | 9.8 | 19 | 9.8 | 38 | 9.8 | 0.780 | ||
| G2 | 112 | 57.7 | 105 | 54.1 | 217 | 55.9 | ||||
| G3 | 54 | 27.8 | 60 | 30.9 | 114 | 29.4 | ||||
| G4 | 1 | 0.5 | 2 | 1 | 3 | 0.8 | ||||
| GX | 6 | 3.1 | 7 | 3.6 | 13 | 3.4 | ||||
| unknown | 2 | 1 | 1 | 0.5 | 3 | 0.8 | ||||
| Treatment | Surgery | 41 | 21.1 | 38 | 19.6 | 79 | 20.4 | 0.596 | ||
| Radiation | 14 | 7.2 | 12 | 6.2 | 26 | 6.7 | ||||
| Concurrent | 20 | 10.3 | 15 | 7.7 | 35 | 9 | ||||
| Non-concurrent | 2 | 1 | 1 | 0.5 | 3 | 0.8 | ||||
| unknown | 117 | 60.3 | 128 | 66 | 245 | 63.1 | ||||
| Radiation | Yes | 111 | 57.2 | 111 | 57.2 | 222 | 57.2 | 0.127 | ||
| No | 62 | 32 | 60 | 30.9 | 122 | 31.4 | ||||
| unknown | 21 | 10.8 | 23 | 11.9 | 44 | 11.3 | ||||
| Margin | Negative/Close | 144 | 74.2 | 144 | 74.2 | 288 | 74.2 | 0.947 | ||
| Positive | 28 | 14.4 | 25 | 12.9 | 53 | 13.7 | ||||
| unknown | 22 | 11.3 | 38 | 12.9 | 47 | 12.1 | ||||
| T-stage | T1 | 15 | 7.7 | 22 | 11.3 | 37 | 9.5 | 0.087 | ||
| T2 | 51 | 26.3 | 55 | 28.4 | 106 | 27.3 | ||||
| T3 | 55 | 28.4 | 30 | 15.5 | 85 | 21.9 | ||||
| T4 | 51 | 26.3 | 59 | 30.4 | 110 | 28.4 | ||||
| TX | 16 | 8.2 | 18 | 9.3 | 34 | 8.8 | ||||
| unknown | 6 | 3.1 | 10 | 5.2 | 16 | 4.1 | ||||
| N-stage | N0 | 66 | 34 | 53 | 27.3 | 119 | 30.7 | 0.388 | ||
| N1 | 24 | 12.4 | 29 | 14.9 | 53 | 13.7 | ||||
| N2 | 62 | 32 | 62 | 32 | 124 | 32 | ||||
| N3 | 3 | 1.5 | 4 | 2.1 | 7 | 1.8 | ||||
| NX | 32 | 16.5 | 35 | 18 | 67 | 17.3 | ||||
| unknown | 7 | 3.6 | 11 | 5.7 | 18 | 4.6 | ||||
| Invasion | No | 83 | 42.8 | 78 | 40.2 | 161 | 41.5 | 0.323 | ||
| Yes | 55 | 28.4 | 45 | 23.2 | 100 | 25.8 | ||||
| unknown | 56 | 28.9 | 71 | 36.6 | 127 | 32.7 | ||||
| Targeted | No | 100 | 51.5 | 92 | 47.4 | 192 | 49.5 | 0.732 | ||
| Yes | 59 | 30.4 | 63 | 32.5 | 122 | 31.4 | ||||
| unknown | 35 | 18 | 39 | 20.1 | 74 | 19.1 | ||||
| CD274 | High | 32 | 16.5 | 65 | 33.5 | 97 | 25 | <0.0001 | ||
| Low | 63 | 32.5 | 34 | 17.5 | 97 | 25 | ||||
| Medium | 99 | 51 | 95 | 49 | 194 | 50 | ||||
| PDCD1 | High | 8 | 4.1 | 89 | 45.9 | 97 | 25 | <0.0001 | ||
| Low | 89 | 45.9 | 8 | 4.1 | 97 | 25 | ||||
| medium | 97 | 50 | 94 | 50 | 194 | 50 |
a. McNemar's Test (and the Bowker's Test when appropriate)
Abbreviations: Alcohol, alcohol history; Packs/year, packs/year smoked, HPV, HPV status assessed by ISH testing; P16, HPV status assessed by p16 testing; EGFR status, Epidermal growth factor receptor amplification status; Anatomic, anatomic neoplasm subdivision; Grade, neoplasm histologic grade; Concurrent, concurrent chemotherapy; Non-concurrent, chemotherapy not administered concurrently; Invasion, lymphovascular invasion present; Targeted, targeted molecular therapy; RR, radioresistant group; RS, radiosensitive group.